Teclistamab is a new antibody drug for multiple myeloma patients. It is classified as a bispecific antibodies. These antibodies are capable of binding to T-cells and also to the surface of cancer cells, which in this case are myeloma cancer cells.
Teclistamab is T-cell redirecting antibody that engages immune cells of body as T-cells by binding to CD3 receptors. It other site binds to myeloma cancer cell antigen called B-cell maturation antigen (BCMA).
A recent study published in NEJM in August 2022 has reported response rate as high as 63%. The drug reportedly produced complete response in 39.4%. Teclistamab was able to produce durable responses and has shown efficacy in patients who already progressed on at three-lines of anti-myeloma therapies.
https://www.nejm.org/doi/full/10.1056/NEJMoa2203478
